Trial
NCT04641975
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
—
Condition
Overactive Bladder (OAB)
Intervention
Mirabegron
Why stopped
Termination due to operational futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-14